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Study determined that the disability-
adjusted life years from nonmelanoma
skin cancer are equal to those from
melanoma and bladder cancer (Global
Burden of Disease Study, 2013). Finally,
apparent pragmatists argue that the cost
of a definitive randomized controlled
trial would be too great. This perspec-
tive seems short-sighted for our specialty,
as the care of nonmelanoma skin cancer
is a key part of our practices (Rogers
et al., 2010; Connolly et al., 2012), the
cost to Medicare is an important health-
care expense (Housman et al., 2003)
and the potential misuse of health-care
resources is significant enough to engen-
der substantial scrutiny by regulators
(Elston, 2013).
We in Dermatology should be at the
forefront of calls to the National Insti-
tutes of Health and other agencies to
address scientifically the gap in evi-
dence to guide care for the most com-
mon malignancy. We need a definitive
randomized controlled trial to deter-
mine the superior surgical treatment for
important subgroups of nonmelanoma
skin cancers. Only with data can we
know that we have ‘‘properly selected
skin cancer treatments.’’
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TO THE EDITOR
Rogers et al. (2014) appear to have
taken umbrage at my commentary
(Stern, 2013). For properly selected non-
melanoma skin cancers (NMSCs),
Mohs surgery is an excellent and often
optimal option. For these tumors, the
time, overhead, and intensity required
may justify the current reimbursement.
However, for many primary NMSCs
treated with Mohs surgery, as currently
priced and practiced in the United
States, Mohs is not a good value pro-
position for those who pay for medical
care and provides little additional
benefit to patients (https://www.federa
lregister.gov/, accessed 23 September
2013 and Wilson et al., 2011).
Standard therapies of primary NMSCs
outside of the H-zone and scalp, admini-
stered by those with procedural training,
have slightly higher recurrence rates, are
less expensive, take less patient time,
and usually give comparable results.
Differences in patient populations are
highly unlikely to explain the excep-
tional variability (46 and 416 fold
among States) in the percent of all
NMSCs of the face, neck, scalp, and
other sites, respectively, treated with
Mohs (Donaldson and Coldiron (2012);
Stern (2013)). The proportion of NMSCs
treated with Mohs was generally higher
in the States with more Mohs surgeons
per capita, particularly for tumors not on
the head. There must be greater vari-
ability among individual dermatologic
surgeons in the proportion of NMSCs
they treat with Mohs, for which the
clinical benefits justify the higher cost.
The number of Mohs procedures
performed has grown as the number of
Mohs Surgeons has increased (Maxwell
et al., 2007; Rogers and Coldiron,
2012). Almost certainly, the economics
and supply of Mohs surgery rather than
medical indications are the strongest
drivers of increased utilization. From
1992 to 2002, utilization rates of
Mohs for Medicare beneficiaries tripled
(Maxwell et al., 2007). Extrapolation
from these and 2009 data indicate a
rate of two Mohs surgeries per oneAccepted article preview online 24 October 2013; published online 21 November 2013
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hundred Medicare beneficiaries in
2013, about ten times the rate in 1992
(Donaldson and Coldiron, 2012).
Rogers et al. (2014) find Mosterd’s to
be an imperfect study, as are all studies.
However, it is the best study of Mohs
of which I am aware (Mosterd et al.,
2008). The Mohs surgeons who partici-
pated in this study are experienced
and well qualified. Avoiding a single
recurrence on areas most likely to be
appropriate for Mohs (H-zone, scalp,
recurrences, aggressive histologic sub-
types) costs at least $25,000, and pro-
bably substantially more, which may be
reasonable for tumors at sites where
recurrence would result in substantial
morbidity.
The letter by Rogers et al. (2014)
reflects the guild-like structure of the
Mohs College. Wikipedia describes a
guild as an association of artisans
who control the practice of their craft
(http://www.wikipedia.com, accessed 23
September 2013). Guilds were common
in medieval times but are largely
extinct. Guilds have some attributes of
professional associations, trade unions,
cartels and secret societies. Members are
usually self-employed and often have
apprentices (fellows). An effective guild
increases its members’ income.
The Mohs College has been a
successful guild. Compensation for
Mohs surgeons is substantially higher
than that of other dermatologists. Mohs
surgeons are the eighth most highly paid
hospital-employed specialists ($586,000
in 2012) and have higher incomes than
cardiovascular surgeons (http://www.
beckershospitalreview.com/compensation-
issues, 23 September 2013). It is com-
mon knowledge that Mohs surgeons in
private practice receive substantially
higher compensations than their hospi-
tal-employed colleagues. Yet, Mohs is
not recognized as a specialty by the
American Board of Medicine Specialties
and the Mohs training, per se, is not
accredited. Rather, and appropriately
so, experience with Mohs is one part
of the ACGME approved Procedural
Dermatology training. The Mohs Col-
lege and the separate American Society
for Mohs Surgery advocate for Mohs
surgery and both offer ‘‘Fellow’’ status.
When appropriately utilized, it seems
like Mohs is a good value proposition
and justification for current reimburse-
ment level seem likely for recurrent
NMSCs and primary tumors in the ana-
tomic locations that meet specific cri-
teria (Flohil et al., 2013), but robust data
to confirm this are lacking (Hamilton
et al., 2013). The justification for the use
of Mohs is weak for tumors with low risk
of recurrence or for which the morbi-
dity from recurrence is low. The federal
government has identified Mohs surgery
as an ‘‘overvalued’’ procedure, i.e., one
for which the overhead, time, and
intensity required for the procedure do
not justify current payment (Federal
Register, 2013).
Rogers et al. (2014) comment on the
impracticality of studying Mohs with-
out ‘‘industry sponsorship’’ are fatuous.
Their power calculation assumes about
a one percent difference between Mohs
and excision recurrence rates, a rate
which would not justify the higher cost
of Mohs for most primary NMSCs so
treated. To detect a 2 percent difference
(4 vs. 2%) would require less than
half as many patients as they indi-
cate. Enrolling less than 2 percent of
Mohs cases performed by the 52 highest
volumes of Mohs surgeons, each of
whose revenues substantially exceed
an average of $2,000,000 per year
from Medicare alone would be
sufficient.
Rogers et al. (2014) argue listing that
Mohs is not substantially more expen-
sive than alternative procedures. Most of
the studies they cite were published in
the ‘‘official journal’’ of the Mohs
College, and do not provide compari-
sons of Mohs to cost-effective alterna-
tives. Their argument lacks face validity.
Their letter is a superb illustration
of the saying: ‘‘When someone says,
‘It’s not the money, it’s the prin-
ciple of the thing,’ it is the money.’’
Now that Mohs is a multi-billion dollar
industry, I fear those who control
reimbursement will react to the current
excesses by limiting access of patients
for whom Mohs is a good value
proposition or setting reimbursement at
such low levels that surgeons who
utilize Mohs appropriately will not be
fairly compensated.
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